Scotiabank analyst Louise Chen raised the firm’s price target on Bristol Myers (BMY) to $60 from $53 and keeps a Sector Perform rating on the shares. The firm believes the upcoming year is “catalyst-rich” and its inexpensive valuation makes the stock appear attractive, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
- Bristol-Myers Squibb Targets Autism Irritability With New Phase 3 Trial, Expanding Its Neuroscience Reach
- Bristol-Myers Squibb Quietly Expands Pipeline With New First-in-Human Study of BMS-986521
- Bristol-Myers Squibb’s Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story
- Bristol Myers upgraded to Buy from Neutral at UBS